+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cost of Prescription Drug-Related Morbidity and Mortality



Cost of Prescription Drug-Related Morbidity and Mortality



Annals of PharmacoTherapy 52(9): 829-837



Public attention and recent US Congressional activity has intensified focus on escalating medication prices. However, the actual cost of medication use extends beyond the up-front cost of purchasing medicines. It also encompasses the additional medical costs of morbidity and mortality resulting from nonoptimized medication regimens, including medication nonadherence. Applying the most current nationally representative data sources, our goal was to estimate the cost of prescription drug-related morbidity and mortality in the United States. Total costs of nonoptimized prescription drug use and average pathway costs for a patient who experienced a treatment failure (TF), a new medical problem (NMP), or a TF and NMP were modeled in Microsoft Excel (Microsoft Corporation, Redmond, WA) and TreeAge Pro Healthcare, v2014 (TreeAge Software, Inc, Williamstown, MA), respectively. The estimated annual cost of prescription drug-related morbidity and mortality resulting from nonoptimized medication therapy was $528.4 billion in 2016 US dollars, with a plausible range of $495.3 billion to $672.7 billion. The average cost of an individual experiencing TF, NMP, or TF and NMP after initial prescription use were $2481 (range: $2233, $2742), $2610 (range: $2374, $2848) and $2572 (range: $2408, $2751), respectively. The estimated annual cost of drug-related morbidity and mortality resulting from nonoptimized medication therapy was $528.4 billion, equivalent to 16% of total US health care expenditures in 2016. We propose expansion of comprehensive medication management programs by clinical pharmacists in collaborative practices with physicians and other prescribers as an effective and scalable approach to mitigate these avoidable costs and improve patient outcomes.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057116853

Download citation: RISBibTeXText

PMID: 29577766

DOI: 10.1177/1060028018765159


Related references

Drug-related morbidity and mortality. A cost-of-illness model. Archives of Internal Medicine 155(18): 1949-1956, 1995

Drug-related morbidity and mortality: updating the cost-of-illness model. Journal of the American Pharmaceutical Association 41(2): 192-199, 2001

The health care cost of drug-related morbidity and mortality in nursing facilities. Archives of Internal Medicine 157(18): 2089-2096, 1997

Cost-effectiveness of consultant pharmacists in managing drug-related morbidity and mortality at nursing facilities. American Journal of Health-System Pharmacy 55(15): 1588-1594, 1998

Cost-related information to be provided by computerised drug-prescription systems to promote cost-effective prescribing. Pharmacoeconomics 12(2 Pt 1): 130-139, 1997

Correlations between prescription opioid analgesic dispensing levels and related mortality and morbidity in Ontario, Canada, 2005-2011. Drug and Alcohol Review 33(1): 19-26, 2015

Addressing cost-related barriers to prescription drug use in Canada. Cmaj 186(4): 276-280, 2014

Prescription drug co-payments and cost-related medication underuse. Health Economics Policy and Law 3(Pt 1): 51-67, 2008

Morbidity, mortality and cost-related outcomes in acute pancreatitis A prospective study. Gastroenterology 112(4 Suppl. ): A15, 1997

Morbidity, mortality and cost from HPV-related oropharyngeal cancer: Impact of 2-, 4- and 9-valent vaccines. Human Vaccines and Immunotherapeutics 12(6): 1343-1347, 2016

Surveillance of prescription drug-related mortality using death certificate data. Drug Safety 30(6): 533-540, 2007

Drug-Related Morbidity in Brazil: A Cost-of-Illness Model. Value in Health Regional Issues 17: 150-157, 2018

What is wrong with non-respondents? Alcohol-, drug- and smoking-related mortality and morbidity in a 12-year follow-up study of respondents and non-respondents in the Danish Health and Morbidity Survey. Addiction 110(9): 1505-1512, 2015

Mortality, morbidity, and cost-accounting related to coronary artery bypass graft surgery in the elderly. Annals of Thoracic Surgery 39(5): 426-432, 1985

Drug-related morbidity and mortality: an economic and clinical perspective. Managed Care 11(2 Suppl): 12-15, 2002